Annual EBITDA
-$128.20 M
+$27.39 M+17.61%
31 December 2023
Summary:
Adaptimmune Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$128.20 million, with the most recent change of +$27.39 million (+17.61%) on 31 December 2023. During the last 3 years, it has fallen by -$2.39 million (-1.90%). ADAP annual EBITDA is now -1279.75% below its all-time high of -$9.29 million, reached on 30 June 2013.ADAP EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$12.86 M
-$86.17 M-117.54%
30 September 2024
Summary:
Adaptimmune Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$12.86 million, with the most recent change of -$86.17 million (-117.54%) on 30 September 2024. Over the past year, it has increased by +$29.16 million (+69.40%). ADAP quarterly EBITDA is now -117.54% below its all-time high of $73.31 million, reached on 30 June 2024.ADAP Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$57.18 M
+$29.16 M+33.78%
30 September 2024
Summary:
Adaptimmune Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$57.18 million, with the most recent change of +$29.16 million (+33.78%) on 30 September 2024. Over the past year, it has increased by +$21.62 million (+27.44%). ADAP TTM EBITDA is now -1367.02% below its all-time high of -$3.90 million, reached on 30 September 2014.ADAP TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ADAP EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +17.6% | +69.4% | +27.4% |
| 3 y3 years | -1.9% | +68.4% | +61.9% |
| 5 y5 years | -72.0% | +66.3% | +57.2% |
ADAP EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -1.9% | +17.6% | -117.5% | +81.9% | at high | +67.9% |
| 5 y | 5 years | -72.0% | +17.6% | -117.5% | +81.9% | at high | +67.9% |
| alltime | all time | -1279.8% | +17.6% | -117.5% | +81.9% | -1367.0% | +67.9% |
Adaptimmune Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$12.86 M(-117.5%) | -$57.18 M(-33.8%) |
| June 2024 | - | $73.31 M(-257.9%) | -$86.34 M(-51.5%) |
| Mar 2024 | - | -$46.43 M(-34.8%) | -$178.13 M(+40.8%) |
| Dec 2023 | -$128.20 M(-17.6%) | -$71.20 M(+69.4%) | -$126.50 M(+60.5%) |
| Sept 2023 | - | -$42.02 M(+127.4%) | -$78.80 M(+0.7%) |
| June 2023 | - | -$18.48 M(-455.1%) | -$78.28 M(-23.3%) |
| Mar 2023 | - | $5.20 M(-122.1%) | -$102.00 M(-34.4%) |
| Dec 2022 | -$155.59 M(-0.1%) | -$23.51 M(-43.4%) | -$155.59 M(-9.9%) |
| Sept 2022 | - | -$41.50 M(-1.7%) | -$172.72 M(+0.4%) |
| June 2022 | - | -$42.20 M(-12.8%) | -$171.94 M(+2.6%) |
| Mar 2022 | - | -$48.39 M(+19.1%) | -$167.61 M(+7.7%) |
| Dec 2021 | -$155.68 M(+23.7%) | -$40.63 M(-0.2%) | -$155.68 M(+3.7%) |
| Sept 2021 | - | -$40.73 M(+7.5%) | -$150.12 M(+4.5%) |
| June 2021 | - | -$37.87 M(+3.9%) | -$143.70 M(+7.1%) |
| Mar 2021 | - | -$36.45 M(+3.9%) | -$134.21 M(+6.7%) |
| Dec 2020 | -$125.81 M(-4.5%) | -$35.07 M(+2.2%) | -$125.81 M(+5.7%) |
| Sept 2020 | - | -$34.31 M(+20.9%) | -$119.00 M(-3.2%) |
| June 2020 | - | -$28.38 M(+1.2%) | -$122.88 M(-4.0%) |
| Mar 2020 | - | -$28.05 M(-0.7%) | -$128.02 M(-2.8%) |
| Dec 2019 | -$131.76 M | -$28.26 M(-26.0%) | -$131.76 M(-1.3%) |
| Sept 2019 | - | -$38.18 M(+13.9%) | -$133.51 M(+54.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2019 | - | -$33.52 M(+5.4%) | -$86.40 M(+8.2%) |
| Mar 2019 | - | -$31.80 M(+6.0%) | -$79.83 M(+6.6%) |
| Dec 2018 | -$74.56 M(-0.9%) | -$30.01 M(-436.1%) | -$74.89 M(+2.8%) |
| Sept 2018 | - | $8.93 M(-133.1%) | -$72.85 M(-14.5%) |
| June 2018 | - | -$26.96 M(+0.4%) | -$85.23 M(+5.3%) |
| Mar 2018 | - | -$26.86 M(-4.0%) | -$80.92 M(+7.6%) |
| Dec 2017 | -$75.24 M(+8.2%) | -$27.96 M(+708.9%) | -$75.24 M(+18.5%) |
| Sept 2017 | - | -$3.46 M(-84.7%) | -$63.49 M(-18.2%) |
| June 2017 | - | -$22.64 M(+6.9%) | -$77.61 M(+2.2%) |
| Mar 2017 | - | -$21.18 M(+30.6%) | -$75.92 M(+7.2%) |
| Dec 2016 | -$69.51 M(+176.2%) | -$16.22 M(-7.7%) | -$70.82 M(+29.7%) |
| Sept 2016 | - | -$17.57 M(-16.1%) | -$54.60 M(+16.5%) |
| June 2016 | - | -$20.95 M(+30.3%) | -$46.85 M(+80.9%) |
| Mar 2016 | - | -$16.08 M(+63.8%) | -$25.90 M(+128.6%) |
| Dec 2015 | -$25.16 M(+5.3%) | - | - |
| Sept 2015 | - | -$9.82 M(+551.2%) | -$11.33 M(+109.6%) |
| June 2015 | -$23.91 M(+111.9%) | - | - |
| Dec 2014 | - | -$1.51 M(-61.3%) | -$5.41 M(+38.7%) |
| Sept 2014 | - | -$3.90 M | -$3.90 M |
| June 2014 | -$11.28 M(+21.4%) | - | - |
| June 2013 | -$9.29 M | - | - |
FAQ
- What is Adaptimmune Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics annual EBITDA year-on-year change?
- What is Adaptimmune Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics quarterly EBITDA year-on-year change?
- What is Adaptimmune Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics TTM EBITDA year-on-year change?
What is Adaptimmune Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of ADAP is -$128.20 M
What is the all time high annual EBITDA for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$9.29 M
What is Adaptimmune Therapeutics annual EBITDA year-on-year change?
Over the past year, ADAP annual earnings before interest, taxes, depreciation & amortization has changed by +$27.39 M (+17.61%)
What is Adaptimmune Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of ADAP is -$12.86 M
What is the all time high quarterly EBITDA for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $73.31 M
What is Adaptimmune Therapeutics quarterly EBITDA year-on-year change?
Over the past year, ADAP quarterly earnings before interest, taxes, depreciation & amortization has changed by +$29.16 M (+69.40%)
What is Adaptimmune Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of ADAP is -$57.18 M
What is the all time high TTM EBITDA for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$3.90 M
What is Adaptimmune Therapeutics TTM EBITDA year-on-year change?
Over the past year, ADAP TTM earnings before interest, taxes, depreciation & amortization has changed by +$21.62 M (+27.44%)